What is the purpose of this trial?
This study is designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with Stage IB, II, or IIIA NSCLC who are eligible for surgical resection with curative intent. Neoadjuvant therapy will consist of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy will consist of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy.
Ages: 18 years and older
Dates: 05/03/2017 - 07/31/2023
Last Updated: 05/17/2017
Study HIC#: 1607018082